BRD9

BRD9, or bromodomain-containing protein 9, alias Sarcoma antigen NY-SAR-29, SMARCI2, PRO9856, etc. BRD9 is a protein that is highly expressed in a variety of tumors and consists of two subunits, the N-terminal α-helix and C-terminal β-helical structural domains, respectively.BRD9 expression level in tumor cells is positively correlated with the tumor's malignancy and growth rate, and correlates with clinical parameters such as chemotherapeutic strategy and survival of tumor cells.The pharmacological significance of BRD9 lies in its role as a potential biomarker and drug target for tumor diagnosis, treatment, and monitoring.The mechanism of action of BRD9 involves a variety of biological processes, including the regulation of chromatin remodeling, transcriptional regulation, and DNA damage repair.BRD9 participates in the function of chromatin remodeling complexes by recognizing acetylation sites of other proteins through its bromo structural domain. In addition, BRD9 is also associated with DNA damage repair, and its bromo structural domain promotes the interactions between RAD51 and RAD54 by binding to the acetylation site of RAD54, which in turn regulates homologous recombination-mediated DNA repair activity.

Inhibition or knockdown of BRD9 increases the sensitivity of tumor cells to PARP inhibitors and certain chemotherapeutic agents, providing a novel strategy for overcoming tumor drug resistance. The biological significance of BRD9 is very broad, it is not only involved in the processes of tumor cell proliferation, differentiation and migration, but also related to the invasiveness and metastatic ability of tumors.Impaired function of BRD9 reduces the self-renewal ability of human embryonic stem cells and alters their differentiation potential.BRD9-mediated TGF-β/Activin/Nodal pathway has also been demonstrated in the progression of pancreatic and breast cancer cell progression was also confirmed, suggesting that BRD9 plays an important role in tumor development. Thus, BRD9 is a potential target in tumor therapy, and drug development against BRD9 is ongoing.